{"id":578692,"date":"2021-12-10T17:12:01","date_gmt":"2021-12-10T17:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=578692"},"modified":"2021-12-10T17:12:01","modified_gmt":"2021-12-10T17:12:01","slug":"key-players-such-as-eloxx-pharmaceuticals-avrobio-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-cystinosis-market","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/key-players-such-as-eloxx-pharmaceuticals-avrobio-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-cystinosis-market_578692.html","title":{"rendered":"Key Players such as Eloxx Pharmaceuticals, Avrobio, and others are developing therapies to enhance treatment modalities in the Cystinosis market"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1639131597.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Key Players such as Eloxx Pharmaceuticals, Avrobio, and others are developing therapies to enhance treatment modalities in the Cystinosis market\" src=\"https:\/\/www.abnewswire.com\/uploads\/1639131597.png\" alt=\"Key Players such as Eloxx Pharmaceuticals, Avrobio, and others are developing therapies to enhance treatment modalities in the Cystinosis market\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Cystinosis Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Cystinosis market is anticipated to increase due to the launch of novel therapies.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cystinosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Cystinosis market report<\/a><\/strong> thoroughly explains the Cystinosis historical and forecasted epidemiology and the Cystinosis market trends in the 7MM.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Cystinosis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per DelveInsight estimates, the total Cystinosis prevalent cases were <strong>3008<\/strong> in the 7MM in 2020, which is expected to increase during the study period (2018-30).&nbsp;<\/li>\n<li>In the United States, the highest cases were of <strong>Infantile Nephropathic Cystinosis<\/strong>, followed by <strong>Juveline Nephropathic Cystinosis and Non-Nephropathic Cystinosis<\/strong> in 2020.<\/li>\n<li>Leading players in the Cystinosis market include <strong>Eloxx Pharmaceuticals, Avrobio,<\/strong> and others.&nbsp;<\/li>\n<li>Key Cystinosis therapies in the pipeline include <strong>ELX-02, AVR-RD-04,<\/strong> and others.&nbsp;<\/li>\n<li>The Cystinosis market size was found to be <strong>USD 167 million<\/strong> in the 7MM in 2020.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Request for a sample to know more @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cystinosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Cystinosis Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cystinosis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Cystinosis is a disease caused by an abnormal accumulation of a specific amino acid known as cysteine. It is a rare but severe disease with long-term consequences that can affect many body parts. Cystinosis is classified into three types based on when symptoms first appear (known as onset): infantile (early-onset) cystinosis, late childhood or adolescent (late-onset) cystinosis, and adult cystinosis.<\/p>\n<p style=\"text-align: justify;\"><strong>Cystinosis Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\">The Cystinosis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Cystinosis Total Prevalent Cases&nbsp;<\/li>\n<li>Cystinosis Diagnosed Prevalent Cases&nbsp;<\/li>\n<li>Cystinosis Type-Specific Diagnosed Prevalent Cases&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cystinosis Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">There is currently no cure for Cystinosis, and treatment is limited to a few approved therapies that provide symptomatic relief. In the United States, three therapies are currently approved, one for ocular cystinosis and the other two for nephropathic cystinosis. The approved Cystinosis therapies include Procysbi (cysteamine bitartrate), Cystagon (cysteamine bitartrate), Cystaran (cysteamine hydrochloride), and Cystadrops (cysteamine hydrochloride).&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cystinosis Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">The Cystinosis market size was found to be <strong>USD 167 million<\/strong> in the 7MM in 2020.<\/p>\n<p style=\"text-align: justify;\">The Cystinosis market will increase due to the introduction of new therapies such as <strong>ELX-02, AVR-RD-04,<\/strong> and others during the forecast period (2021-30).<\/p>\n<p style=\"text-align: justify;\">Get a detailed analysis of the market @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cystinosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Cystinosis Market Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cystinosis Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\">ELX-02: Eloxx Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">AVR-RD-04 (CTNS-RD-04): Avrobio<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong>&nbsp;<\/p>\n<table border=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1.<\/p>\n<\/td>\n<td>\n<p>Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2.<\/p>\n<\/td>\n<td>\n<p>Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3.<\/p>\n<\/td>\n<td>\n<p>Cystinosis Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4.<\/p>\n<\/td>\n<td>\n<p>Executive Summary of Cystinosis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5.<\/p>\n<\/td>\n<td>\n<p>Key Events<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.<\/p>\n<\/td>\n<td>\n<p>Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.<\/p>\n<\/td>\n<td>\n<p>Treatment and Management of Cystinosis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8.<\/p>\n<\/td>\n<td>\n<p>Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9.<\/p>\n<\/td>\n<td>\n<p>Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10.<\/p>\n<\/td>\n<td>\n<p>Marketed Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11.<\/p>\n<\/td>\n<td>\n<p>Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12.<\/p>\n<\/td>\n<td>\n<p>Cystinosis: Seven Major Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13.<\/p>\n<\/td>\n<td>\n<p>KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14.<\/p>\n<\/td>\n<td>\n<p>Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15.<\/p>\n<\/td>\n<td>\n<p>Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16.<\/p>\n<\/td>\n<td>\n<p>SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17.<\/p>\n<\/td>\n<td>\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18.<\/p>\n<\/td>\n<td>\n<p>Market Access and Reimbursement<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19.<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20.<\/p>\n<\/td>\n<td>\n<p>DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>21.<\/p>\n<\/td>\n<td>\n<p>Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>22.<\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">Get in touch with our business executive for <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Healthcare Due Diligence Services<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/nephropathic-cystinosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Nephropathic Cystinosis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <strong>&#8220;Nephropathic Cystinosis &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/strong> report delivers an in-depth understanding of the Nephropathic Cystinosis , historical and forecasted epidemiology as well as the Nephropathic Cystinosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=key-players-such-as-eloxx-pharmaceuticals-avrobio-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-cystinosis-market\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=key-players-such-as-eloxx-pharmaceuticals-avrobio-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-cystinosis-market\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cystinosis Market The Cystinosis market is anticipated to increase due to the launch of novel therapies. DelveInsight&rsquo;s Cystinosis market report thoroughly explains the Cystinosis historical and forecasted epidemiology and the Cystinosis market trends in the 7MM. Key Takeaways from the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/key-players-such-as-eloxx-pharmaceuticals-avrobio-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-cystinosis-market_578692.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-578692","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/578692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=578692"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/578692\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=578692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=578692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=578692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}